Brainsway (NASDAQ:BWAY – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Brainsway to similar businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.
Valuation & Earnings
This table compares Brainsway and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Brainsway | $52.22 million | $7.57 million | 17.54 |
| Brainsway Competitors | $1.90 billion | $135.83 million | 5.64 |
Brainsway’s rivals have higher revenue and earnings than Brainsway. Brainsway is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Brainsway has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Brainsway’s rivals have a beta of 2.58, meaning that their average share price is 158% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Brainsway and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Brainsway | 0 | 2 | 4 | 0 | 2.67 |
| Brainsway Competitors | 4322 | 10606 | 18420 | 841 | 2.46 |
Brainsway currently has a consensus target price of $18.20, indicating a potential upside of 107.53%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 27.83%. Given Brainsway’s stronger consensus rating and higher probable upside, equities analysts clearly believe Brainsway is more favorable than its rivals.
Profitability
This table compares Brainsway and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Brainsway | 15.54% | 13.09% | 8.50% |
| Brainsway Competitors | -190.60% | -186.87% | -21.75% |
Institutional and Insider Ownership
30.1% of Brainsway shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Brainsway beats its rivals on 8 of the 13 factors compared.
About Brainsway
BrainsWay Ltd. is an Israel-based medical technology company that develops and commercializes noninvasive treatments for mental health and neurological conditions. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields and specially designed H-Coils to stimulate brain regions associated with specific conditions. The company’s Deep TMS systems are used for conditions including major depressive disorder, obsessive-compulsive disorder and smoking addiction.
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
